Buspirone

Buspirone
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Buspirone is an anti anxiety drug that is FDA approved for the treatment of anxiety disorders or the short-term relief of the symptoms of anxiety. Common adverse reactions include nausea, dizziness, headache, somnolence and feeling nervous.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Anxiety Disorders

Dosing information

• Recommended initial dose:15 mg daily (7.5 mg b.i.d.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. The maximum daily dosage should not exceed 60 mg per day. In clinical trials allowing dose titration, divided doses of 20 to 30 mg per day were commonly employed.

• The bioavailability of buspirone is increased when given with food as compared to the fasted state . Consequently, patients should take buspirone in a consistent manner with regard to the timing of dosing; either always with or always without food.

• When buspirone is to be given with a potent inhibitor of CYP3A4 the dosage recommendations described in the precaution drug interaction section should be followed.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

• There is limited information regarding Off-Label Guideline-Supported Use of buspirone in adult patients.

Non–Guideline-Supported Use

Depression

Dosing information

• 5 mg administered 3 times daily for 4 weeks

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Buspirone FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

• There is limited information regarding Off-Label Guideline-Supported Use of buspirone in pediatric patients.

Non–Guideline-Supported Use

• There is limited information regarding Off-Label Non–Guideline-Supported Use of buspirone in pediatric patients.

Contraindications

• Buspirone hydrochloride ablets, USP are contraindicated in patients hypersensitive to buspirone hydrochloride.

Warnings

• The administration of buspirone to a patient taking a monoamine oxidase inhibitor (MAOI) may pose a hazard. There have been reports of the occurrence of elevated blood pressure when buspirone hydrochloride has been added to a regimen including an MAOI. Therefore, it is recommended that buspirone not be used concomitantly with an MAOI.

• Because buspirone has no established antipsychotic activity, it should not be employed in lieu of appropriate antipsychotic treatment.

PRECAUTIONS

General

• Interference with Cognitive and Motor Performance

• Studies indicate that buspirone is less sedating than other anxiolytics and that it does not produce significant functional impairment. However, its CNS effects in any individual patient may not be predictable. Therefore, patients should be cautioned about operating an automobile or using complex machinery until they are reasonably certain that buspirone treatment does not affect them adversely.

• While formal studies of the interaction of buspirone hydrochloride with alcohol indicate that buspirone does not increase alcohol-induced impairment in motor and mental performance, it is prudent to avoid concomitant use of alcohol and buspirone.

• Potential for Withdrawal Reactions in Sedative/Hypnotic/Anxiolytic Drug-Dependent Patients

• Because buspirone does not exhibit cross-tolerance with benzodiazepines and other common sedative/hypnotic drugs, it will not block the withdrawal syndrome often seen with cessation of therapy with these drugs. Therefore, before starting therapy with buspirone, it is advisable to withdraw patients gradually, especially patients who have been using a CNS-depressant drug chronically, from their prior treatment. Rebound or withdrawal symptoms may occur over varying time periods, depending in part on the type of drug, and its effective half-life of elimination.

• The syndrome of withdrawal from sedative/hypnotic/anxiolytic drugs can appear as any combination of irritability, anxiety, agitation, insomnia, tremor, abdominal cramps, muscle cramps, vomiting, sweating, flu-like symptoms without fever, and occasionally, even as seizures.

• Possible Concerns Related to Buspirone’s Binding to Dopamine Receptors

• Because buspirone can bind to central dopamine receptors, a question has been raised about its potential to cause acute and chronic changes in dopamine-mediated neurological function (e.g., dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia). Clinical experience in controlled trials has failed to identify any significant neuroleptic-like activity; however, a syndrome of restlessness, appearing shortly after initiation of treatment, has been reported in some small fraction of buspirone-treated patients. The syndrome may be explained in several ways. For example, buspirone may increase central nor adrenergic activity; alternatively, the effect may be attributable to dopaminergic effects (i.e., represent akathisia).

Adverse Reactions

Clinical Trials Experience

Commonly Observed

• The more commonly observed untoward events associated with the use of buspirone not seen at an equivalent incidence among placebo-treated patients include dizziness, nausea, headache, nervousness, lightheadedness, and excitement.

Associated with Discontinuation of Treatment

• One guide to the relative clinical importance of adverse events associated with buspirone is provided by the frequency with which they caused drug discontinuation during clinical testing. Approximately 10% of the 2200 anxious patients who participated in the buspirone premarketing clinical efficacy trials in anxiety disorders lasting 3 to 4 weeks discontinued treatment due to an adverse event. The more common events causing discontinuation included: central nervous system disturbances (3.4%), primarily dizziness, insomnia, nervousness, drowsiness, and lightheaded feeling; gastrointestinal disturbances (1.2%), primarily nausea; and miscellaneous disturbances (1.1%), primarily headache and fatigue. In addition, 3.4% of patients had multiple complaints, none of which could be characterized as primary.

Incidence in Controlled Clinical Trials

• The table that follows enumerates adverse events that occurred at a frequency of 1% or more among buspirone hydrochloride patients who participated in 4 week, controlled trials comparing buspirone with placebo. The frequencies were obtained from pooled data for 17 trials. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Comparison of the cited figures, however, does provide the prescribing physician with some basis for estimating the relative contribution of drug and non drug factors to the side-effect incidence rate in the population studied.

This image is provided by the National Library of Medicine.

Other Events Observed During the Entire Premarketing Evaluation of Buspirone

• During its premarketing assessment, buspirone was evaluated in over 3500 subjects. This section reports event frequencies for adverse events occurring in approximately 3000 subjects from this group who took multiple doses of buspirone in the dose range for which buspirone is being recommended (i.e., the modal daily dose of buspirone fell between 10 and 30 mg for 70% of the patients studied) and for whom safety data were systematically collected. The conditions and duration of exposure to buspirone varied greatly, involving well-controlled studies as well as experience in open and uncontrolled clinical settings. As part of the total experience gained in clinical studies, various adverse events were reported. In the absence of appropriate controls in some of the studies, a causal relationship to buspirone hydrochloride treatment cannot be determined. The list includes all undesirable events reasonably associated with the use of the drug.

• The following enumeration by organ system describes events in terms of their relative frequency of reporting in this data base.

• The following definitions of frequency are used: frequent adverse events are defined as those occurring in at least 1/100 patients. Infrequent adverse events are those occurring in 1/100 to 1/1000 patients, while rare events are those occurring in less than 1/1000 patients.

Cardiovascular

• Frequent was non specific chest pain; infrequent were syncope, hypotension, and hypertension; rare were cerebrovascular accident, congestive heart failure, myocardial infarction, cardiomyopathy, and bradycardia.

Central Nervous System

• Frequent were dream disturbances; infrequent were depersonalization, dysphoria, noise intolerance, euphoria , akathisia, fearfulness, loss of interest, dissociative reaction, hallucinations, involuntary movements, slowed reaction time, suicidal ideation, and seizures; rare were feelings of claustrophobia, cold intolerance, stupor, and slurred speech and psychosis.

ENT

• Frequent were tinnitus, sore throat, and nasal congestion; infrequent were redness and itching of the eyes, altered taste, altered smell, and conjunctivitis; rare were inner ear abnormality, eye pain, photophobia, and pressure on eyes.

Endocrine

• Rare were galactorrhea and thyroid abnormality.

Gastrointestinal

• Infrequent were flatulence, anorexia, increased appetite, salivation, irritable colon, and rectal bleeding; rare was burning of the tongue.

Genitourinary

• Infrequent were urinary frequency, urinary hesitancy, menstrual irregularity and spotting, and dysuria; rare were amenorrhea, pelvic inflammatory disease, enuresis, and nocturia.

Musculoskeletal

• Infrequent were muscle cramps, muscle spasms, rigid/stiff muscles, and arthralgias; rare was muscle weakness.

Respiratory

• Infrequent were hyperventilation, shortness of breath, and chest congestion; rare was epistaxis.

Sexual Function

• Infrequent were decreased or increased libido; rare were delayed ejaculation and impotence.

Skin

• Infrequent were edema, pruritus, flushing, easy bruising, hair loss, dry skin, facial edema, and blisters; rare were acne and thinning of nails.

Clinical Laboratory

• Infrequent were increases in hepatic aminotransferases (SGOT, SGPT); rare were eosinophilia, leukopenia, and thrombocytopenia.

Miscellaneous

• Infrequent were weight gain, fever, roaring sensation in the head, weight loss, and malaise; rare were alcohol abuse, bleeding disturbance, loss of voice, and hiccoughs.

Postmarketing Experience

• Postmarketing experience has shown an adverse experience profile similar to that given above. voluntary reports since introduction have included rare occurrences of allergic reactions (including urticaria), angioedema, cogwheel rigidity, dizziness (rarely reported as vertigo), dystonic reactions (including dystonia), ataxias, extrapyramidal symptoms, dyskinesias (acute and tardive), ecchymosis, emotional lability, serotonin syndrome, transient difficulty with recall, urinary retention, visual changes (including tunnel vision), parkinsonism, akathisia, restless leg syndrome, and restlessness. Because of the uncontrolled nature of these spontaneous reports, a causal relationship to buspirone treatment has not been determined.

Drug Interactions

Psychotropic Agents

MAO inhibitors

• It is recommended that buspirone not be used concomitantly with MAO inhibitors.

Amitriptyline

• After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed.

Diazepam

• After addition of buspirone to the diazepam dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) were observed for diazepam, but increases of about 15% were seen for nordiazepam, and minor adverse clinical effects (dizziness, headache, and nausea) were observed.

Haloperidol

• In a study in normal volunteers, concomitant administration of buspirone and haloperidol resulted in increased serum haloperidol concentrations. The clinical significance of this finding is not clear.

Nefazodone

Trazodone

• There is one report suggesting that the concomitant use of trazodone hydrochloride and buspirone may have caused 3 to 6 fold elevations on SGPT (ALT) in a few patients. In a similar study attempting to replicate this finding, no interactive effect on hepatic transaminases was identified.

Triazolam/flurazepam

• Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine.

Other psychotropics

• Because the effects of concomitant administration of buspirone with most other psychotropic drugs have not been studied, the concomitant use of buspirone with other CNS-active drugs should be approached with caution.

Inhibitors and Inducers of Cytochrome P450 3A4 [CYP3A4]

• Buspirone has been shown in vitro to be metabolized by CYP3A4. This finding is consistent with the in vivo interactions observed between buspirone and the following:

Diltiazem and verapamil

• In a study of nine healthy volunteers, coadministration of buspirone (10 mg as a single dose) with verapamil (80 mg t.i.d.) or diltiazem (60 mg t.i.d.) increased plasma buspirone concentrations (verapamil increased AUC and Cmax of buspirone 3.4 fold while diltiazem increased AUC and Cmax 5.5 fold and 4 fold, respectively). Adverse events attributable to buspirone may be more likely during concomitant administration with either diltiazem or verapamil. Subsequent dose adjustment may be necessary and should be based on clinical assessment.

Erythromycin

• In a study in healthy volunteers, coadministration of buspirone (10 mg as a single dose) with erythromycin (1.5 g/day for 4 days) increased plasma buspirone concentrations (5 fold increase in Cmax and 6 fold increase in AUC). These pharmacokinetic interactions were accompanied by an increased incidence of side effects attributable to buspirone. If the two drugs are to be used in combination, a low dose of buspirone (e.g., 2.5 mg b.i.d.) is recommended. Subsequent dose adjustment of either drug should be based on clinical assessment.

Grapefruit juice

• In a study in healthy volunteers, coadministration of buspirone (10 mg as a single dose) with grapefruit juice (200 mL double-strength t.i.d. for 2 days) increased plasma buspirone concentrations (4.3 fold increase in Cmax; 9.2 fold increase in AUC). Patients receiving buspirone should be advised to avoid drinking such large amounts of grapefruit juice.

Itraconazole

• In a study in healthy volunteers, coadministration of buspirone (10 mg as a single dose) with itraconazole (200 mg/day for 4 days) increased plasma buspirone concentrations (13 fold increase in Cmax and 19 fold increase in AUC). These pharmacokinetic interactions were accompanied by an increased incidence of side effects attributable to buspirone. If the two drugs are to be used in combination, a low dose of buspirone (e.g., 2.5 mg q.d.) is recommended. Subsequent dose adjustment of either drug should be based on clinical assessment.

Nefazodone

• In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg b.i.d.) with nefazodone (250 mg b.i.d.) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-PP. With 5 mg b.i.d. doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (HO-NEF) (17%) and meta-chlorophenylpiperazine (9%). Slight increases in Cmax were observed for nefazodone (8%) and its metabolite HO-NEF (11%). Subjects receiving buspirone 5 mg b.i.d. and nefazodone 250 mg b.i.d. experienced lightheadedness, asthenia, dizziness, and somnolence, adverse events also observed with either drug alone. If the two drugs are to be used in combination, a low dose of buspirone (e.g., 2.5 mg q.d.) is recommended. Subsequent dose adjustment of either drug should be based on clinical assessment.

Rifampin

• In a study in healthy volunteers, coadministration of buspirone (30 mg as a single dose) with rifampin (600 mg/day for 5 days) decreased the plasma concentrations (83.7% decrease in Cmax; 89.6% decrease in AUC) and pharmacodynamic effects of buspirone. If the two drugs are to be used in combination, the dosage of buspirone may need adjusting to maintain anxiolytic effect.

Other inhibitors and inducers of CYP3A4

• Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone, or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. If a patient has been titrated to a stable dosage on buspirone, a dose adjustment of buspirone may be necessary to avoid adverse events attributable to buspirone or diminished anxiolytic activity. Consequently, when administered with a potent inhibitor of CYP3A4, a low dose of buspirone used cautiously is recommended. When used in combination with a potent inducer of CYP3A4 the dosage of buspirone may need adjusting to maintain anxiolytic effect.

Other Drugs

Cimetidine

• Coadministration of buspirone with cimetidine was found to increase Cmax (40%) and Tmax (2 fold), but had minimal effects on the AUC of buspirone.

Protein Binding

• In vitro, buspirone does not displace tightly bound drugs like phenytoin, propanolol, and warfarin from serum proteins. However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin. The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium. In vitro, buspirone may displace less firmly bound drugs like digoxin. The clinical significance of this property is unknown.

• Therapeutic levels of aspirin, desipramine, diazepam, flurazepam, ibuprofen, propranolol , thioridazine, and tolbutamide had only a limited effect on the extent of binding of buspirone to plasma proteins.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): B

• No fertility impairment or fetal damage was observed in reproduction studies performed in rats and rabbits at buspirone doses of approximately 30 times the maximum recommended human dose. In humans, however, adequate and well-controlled studies during pregnancy have not been performed. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pregnancy Category (AUS):

• The effect of buspirone on labor and delivery in women is unknown. No adverse effects were noted in reproduction studies in rats.

Labor and Delivery

There is no FDA guidance on use of Buspirone during labor and delivery.

Nursing Mothers

• The extent of the excretion in human milk of buspirone or its metabolites is not known. In rats, however, buspirone and its metabolites are excreted in milk. Buspirone administration to nursing women should be avoided if clinically possible.

Pediatric Use

• The safety and effectiveness of buspirone were evaluated in two placebo-controlled 6 week trials involving a total of 559 pediatric patients (ranging from 6 to 17 years of age) with GAD. Doses studied were 7.5 mg to 30 mg b.i.d. (15 to 60 mg/day). There were no significant differences between buspirone and placebo with regard to the symptoms of GAD following doses recommended for the treatment of GAD in adults. Pharmacokinetic studies have shown that, for identical doses, plasma exposure to buspirone and its active metabolite, 1-PP, are equal to or higher in pediatric patients than adults. No unexpected safety findings were associated with buspirone in these trials. There are no long-term safety or efficacy data in this population.

Geriatic Use

• In one study of 6632 patients who received buspirone for the treatment of anxiety, 605 patients were ≥ 65 years old and 41 were ≥ 75 years old; the safety and efficacy profiles for these 605 elderly patients (mean age = 70.8 years) were similar to those in the younger population (mean age = 43.3 years). Review of spontaneously reported adverse clinical events has not identified differences between elderly and younger patients, but greater sensitivity of some older patients can not be ruled out.There were no effects of age on the pharmacokinetics of buspirone

Gender

There is no FDA guidance on the use of Buspirone with respect to specific gender populations.

Race

There is no FDA guidance on the use of Buspirone with respect to specific racial populations.

Renal Impairment

• Buspirone is metabolized by the liver and excreted by the kidneys. A pharmacokinetic study in patients with impaired hepatic or renal function demonstrated increased plasma levels and a lengthened half-life of buspirone. Therefore, the administration of buspirone hydrochloride tablets, USP to patients with severe hepatic or renal impairment cannot be recommended.

Hepatic Impairment

• Buspirone is metabolized by the liver and excreted by the kidneys. A pharmacokinetic study in patients with impaired hepatic or renal function demonstrated increased plasma levels and a lengthened half-life of buspirone. Therefore, the administration of buspirone hydrochloride tablets, USP to patients with severe hepatic or renal impairment cannot be recommended.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Buspirone in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Buspirone in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral

Monitoring

• FDA package insert for buspirone contains no information regarding drug monitoring.

IV Compatibility

• There is limited information about the IV compatibility.

Overdosage

Signs and Symptoms

• In clinical pharmacology trials, doses as high as 375 mg/day were administered to healthy male volunteers. As this dose was approached, the following symptoms were observed: nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress. A few cases of overdosage have been reported, with complete recovery as the usual outcome. No deaths have been reported following overdosage with buspirone alone. Rare cases of intentional overdosage with a fatal outcome were invariably associated with ingestion of multiple drugs and/or alcohol, and a causal relationship to buspirone could not be determined. Toxicology studies of buspirone yielded the following LD50 values: mice, 655 mg/kg; rats, 196 mg/kg; dogs, 586 mg/kg; and monkeys, 356 mg/kg. These dosages are 160 to 550 times the recommended human daily dose.

Recommended Overdose Treatment

• General symptomatic and supportive measures should be used along with immediate gastric lavage. Respiration, pulse, and blood pressure should be monitored as in all cases of drug overdosage. No specific antidote is known to buspirone, and dialyzability of buspirone has not been determined.

Pharmacology

Buspirone
Systematic (IUPAC) name
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
Identifiers
CAS number	36505-84-7
ATC code	N05BE01
PubChem	2477
DrugBank	DB00490
Chemical data
Formula	Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox
Mol. mass	385.50314 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	~4%
Protein binding	86-95%
Metabolism	Hepatic mostly via CYP3A4
Half life	2-3 hours
Excretion	Urine (29-63%), Faeces (18-38%)
Therapeutic considerations
Pregnancy cat.	B1(AU) B(US)
Legal status	Prescription Only (S4)(AU) ?(CA) POM(UK) [[Prescription drug|Template:Unicode-only]](US)
Routes	Oral

Mechanism of Action

• The mechanism of action of buspirone is unknown. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. In vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding in vitro or in vivo when tested in preclinical models.

Structure

• Buspirone hydrochloride is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.

• Buspirone hydrochloride is a white crystalline, water soluble compound. Chemically, buspirone hydrochloride is N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,1-cyclopentanediacetamide monohydrochloride, which can be represented by the following structural formula:

This image is provided by the National Library of Medicine.

• Each tablet, for oral administration, contains 5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 9.1 mg, 13.7 mg and 27.4 mg of buspirone free base respectively). The 5 mg and 10 mg tablets are scored so they can be bisected. Thus, the 5 mg tablet can also provide a 2.5 mg dose, and the 10 mg tablet can provide a 5 mg dose. The 15 mg tablets are scored such that they may be bisected or trisected. Thus, a single tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). The 30 mg tablets are scored such that they may be bisected or trisected. Thus, a single tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two-thirds of a tablet), 15 mg (one-half of a tablet), or 10 mg (one-third of a tablet). Buspirone hydrochloride tablets, USP contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.

Pharmacodynamics

• Buspirone has moderate affinity for brain D2-dopamine receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems.

• Buspirone is rapidly absorbed in man and undergoes extensive first-pass metabolism. In a radiolabeled study, unchanged buspirone in the plasma accounted for only about 1% of the radioactivity in the plasma. Following oral administration, plasma concentrations of unchanged buspirone are very low and variable between subjects. Peak plasma levels of 1 to 6 ng/mL have been observed 40 to 90 minutes after single oral doses of 20 mg. The single-dose bioavailability of unchanged buspirone when taken as a tablet is on the average about 90% of an equivalent dose of solution, but there is large variability.

• The effects of food upon the bioavailability of buspirone have been studied in eight subjects. They were given a 20 mg dose with and without food; the area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) of unchanged buspirone increased by 84% and 116% respectively, but the total amount of buspirone immunoreactive material did not change. This suggests that food may decrease the extent of presystemic clearance of buspirone.

• A multiple-dose study conducted in 15 subjects suggests that buspirone has non linear pharmacokinetics. Thus, dose increases and repeated dosing may lead to somewhat higher blood levels of unchanged buspirone than would be predicted from results of single-dose studies.

• An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins. It was also observed that aspirin increased the plasma levels of free buspirone by 23%, while flurazepam decreased the plasma levels of free buspirone by 20%. However, it is not known whether these drugs cause similar effects on plasma levels of free buspirone in vivo, or whether such changes, if they do occur, cause clinically significant differences in treatment outcome. An in vitro study indicated that buspirone did not displace highly protein-bound drugs such as phenytoin, warfarin, and propranolol from plasma protein, and that buspirone may displace digoxin.

Pharmacokinetics

• Buspirone is metabolized primarily by oxidation, which in vitro has been shown to be mediated by cytochrome P450 3A4 (CYP3A4). Several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP), are produced. In animal models predictive of anxiolytic potential, 1-PP has about one quarter of the activity of buspirone, but is present in up to 20 fold greater amounts. However, this is probably not important in humans: blood samples from humans chronically exposed to buspirone hydrochloride do not exhibit high levels of 1-PP; mean values are approximately 3 ng/mL and the highest human blood level recorded among 108 chronically dosed patients was 17 ng/mL, less than 1/200th of 1-PP levels found in animals given large doses of buspirone without signs of toxicity.

• In a single-dose study using 14C-labeled buspirone, 29% to 63% of the dose was excreted in the urine within 24 hours, primarily as metabolites; fecal excretion accounted for 18% to 38% of the dose. The average elimination half-life of unchanged buspirone after single doses of 10 to 40 mg is about 2 to 3 hours.

Special Populations

Age and Gender Effects

• After single or multiple doses in adults, no significant differences in buspirone pharmacokinetics (AUC and Cmax) were observed between elderly and younger subjects or between men and women.

Hepatic Impairment

• After multiple-dose administration of buspirone to patients with hepatic impairment, steady-state AUC of buspirone increased 13 fold compared with healthy subjects.

Renal Impairment

• After multiple-dose administration of buspirone to renally impaired (Clcr = 10 to 70 mL/min/1.73 m2) patients, steady-state AUC of buspirone increased 4 fold compared with healthy (Clcr ≥ 80 mL/min/1.73 m2) subjects.

Race Effects

• The effects of race on the pharmacokinetics of buspirone have not been studied.

Nonclinical Toxicology

• No evidence of carcinogenic potential was observed in rats during a 24 month study at approximately 133 times the maximum recommended human oral dose; or in mice, during an 18 month study at approximately 167 times the maximum recommended human oral dose.

• With or without metabolic activation, buspirone did not induce point mutations in five strains of Salmonella typhimurium (Ames Test) or mouse lymphoma L5178YTK+ cell cultures, nor was DNA damage observed with buspirone in Wi-38 human cells. Chromosomal aberrations or abnormalities did not occur in bone marrow cells of mice given one or five daily doses of buspirone.

Clinical Studies

• There is limited information about the clinical studies.

How Supplied

• Buspirone Hydrochloride Tablets, USP are available as:

• Buspirone Hydrochloride Tablets, USP 5 mg are white ovoid-rectangular, uncoated tablets, with score line on one side and plain on other side. Tablets are packed in the bottles of 100 having NDC 64380-741-06.

• Buspirone Hydrochloride Tablets, USP 10 mg are white ovoid-rectangular, uncoated tablets, with score line on one side and plain on other side. Tablets are packed in the bottles of 100 having NDC 64380-742-06.

• Buspirone Hydrochloride Tablets, USP 15 mg are white rectangular, uncoated tablets, with trisected score lines on both sides. The 15 mg tablet is in xx tablet design and scored so that it can be either bisected or trisected. Tablets are packed in bottles of 60 having NDC 64380-743-03, 100 having NDC 64380-743-06 and 180 having NDC 64380-743-18.

• Buspirone Hydrochloride Tablets, USP 30 mg are white rectangular, uncoated tablets that can either be bisected or trisected. Tablets are packed in bottles of 60 having NDC 64380-744-03.

Storage

• Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° C to 30° C (59° F to 86° F)

Images

Drug Images

{{#ask: Page Name::Buspirone |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Buspirone |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

• To assure safe and effective use of buspirone hydrochloride tablets, USP the following information and instructions should be given to patients:

1. Inform your physician about any medications, prescription or non-prescription, alcohol, or drugs that you are now taking or plan to take during your treatment with buspirone. 2. Inform your physician if you are pregnant, or if you are planning to become pregnant, or if you become pregnant while you are taking buspirone. 3. Inform your physician if you are breast-feeding an infant. 4. Until you experience how this medication affects you, do not drive a car or operate potentially dangerous machinery. 5. You should take buspirone consistently, either always with or always without food. 6. During your treatment with buspirone, avoid drinking large amounts of grapefruit juice.

This image is provided by the National Library of Medicine.

Precautions with Alcohol

• While formal studies of the interaction of buspirone hydrochloride with alcohol indicate that buspirone does not increase alcohol-induced impairment in motor and mental performance, it is prudent to avoid concomitant use of alcohol and buspirone.

Brand Names

• Buspar
• Buspar Dividose
• Vanspar

Look-Alike Drug Names

• Buspirone - Bupropion

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_HCl_NDC_05910658.jpg
 |Drug Name=Buspirone HCl
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=WATSON;658
 |Pill Dosage=10 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=11
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Watson Laboratories, Inc.
 |NDC=05910658

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_HCl_NDC_05910718.jpg
 |Drug Name=Buspirone HCl
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=718
 |Pill Dosage=15 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=13
 |Pill Scoring=4
 |Pill Image=
 |Drug Author=Watson Laboratories, Inc.
 |NDC=05910718

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_498840725.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=Par;725;7;5
 |Pill Dosage=7.5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=9
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Par Pharmaceutical Inc.
 |NDC=498840725

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_510790960.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=M;B3;5;5;5
 |Pill Dosage=15 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=18
 |Pill Scoring=3
 |Pill Image=
 |Drug Author=Mylan Institutional Inc.
 |NDC=510790960

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_510790985.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=M;B1
 |Pill Dosage=5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=9
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Mylan Institutional Inc.
 |NDC=510790985

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_510790986.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=M;B2
 |Pill Dosage=10 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=11
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Mylan Institutional Inc.
 |NDC=510790986

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_581770264.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=buspirone hydrochloride[buspirone]|+sep=;
 |Pill Imprint=ETHEX;264;5;mg
 |Pill Dosage=5 mg
 |Pill Color=Yellow|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=9
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=ETHEX
 |NDC=581770264

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_581770265.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=buspirone hydrochloride[buspirone]|+sep=;
 |Pill Imprint=ETHEX;265;10;mg
 |Pill Dosage=10 mg
 |Pill Color=Yellow|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=11
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=ETHEX
 |NDC=581770265

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_581770309.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=buspirone hydrochloride[buspirone]|+sep=;
 |Pill Imprint=ETHEX;309;5
 |Pill Dosage=15 mg
 |Pill Color=Yellow|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=16
 |Pill Scoring=3
 |Pill Image=
 |Drug Author=ETHEX
 |NDC=581770309

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_00930054.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=TEVA;54
 |Pill Dosage=10 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=8
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Teva Pharmaceuticals USA Inc
 |NDC=00930054

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_00931003.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=TV;1003;5;5;5
 |Pill Dosage=15 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Rectangle
 |Pill Size (mm)=15
 |Pill Scoring=3
 |Pill Image=
 |Drug Author=Teva Pharmaceuticals USA Inc
 |NDC=00931003

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_00935200.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=TV;5200;10;10;10
 |Pill Dosage=30 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Rectangle
 |Pill Size (mm)=17
 |Pill Scoring=3
 |Pill Image=
 |Drug Author=Teva Pharmaceuticals USA Inc
 |NDC=00935200

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_03781140.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=M;B1
 |Pill Dosage=5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=9
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Mylan Pharmaceuticals Inc.
 |NDC=03781140

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_03781150.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=M;B2
 |Pill Dosage=10 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=11
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Mylan Pharmaceuticals Inc.
 |NDC=03781150

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_03781165.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=M;B3
 |Pill Dosage=15 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=18
 |Pill Scoring=3
 |Pill Image=
 |Drug Author=Mylan Pharmaceuticals Inc.
 |NDC=03781165

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_Hydrochloride_NDC_03781175.jpg
 |Drug Name=Buspirone Hydrochloride
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=M;B4;10
 |Pill Dosage=30 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=18
 |Pill Scoring=3
 |Pill Image=
 |Drug Author=Mylan Pharmaceuticals Inc.
 |NDC=03781175

}}

{{#subobject:

 |Page Name=Buspirone
 |Pill Name=Buspirone_HCl_NDC_05910657.jpg
 |Drug Name=Buspirone HCl
 |Pill Ingred=BUSPIRONE HYDROCHLORIDE[BUSPIRONE]|+sep=;
 |Pill Imprint=WATSON;657
 |Pill Dosage=5 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=8
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Watson Laboratories, Inc.
 |NDC=05910657

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_label_01.jpg

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_label_02.jpg

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_label_03.jpg

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_label_04.jpg

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_label_05.jpg

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_label_06.jpg

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_panel_01.png

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_panel_02.png

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_panel_03.png

}}

{{#subobject:

 |Label Page=Buspirone
 |Label Name=Buspirone_panel_04.png

}}